CADTH announced a positive recommendation for Takhzyro (Lanadelumab)

We have great news to share. CADTH announced a positive recommendation for Takhzyro (Lanadelumab). Thank you to all the members who filled out the survey in June, the HAE Canada Advocacy Committee, Board of Directors and the HAE Canada Team for a job well done. Great collaboration with Takeda. You can find the report on CADTH’s website:
https://www.cadth.ca/lanadelumab

The announcement is on newswire.ca:
“We are hopeful that CADTH’s positive recommendation will provide Canadians living with HAE access to a new and useful therapy to help bridge the gap in care”, said Jacquie Badiou, President, Hereditary Angioedema (HAE) Canada. “HAE not only affects patients physically but can have detrimental impacts on one’s quality of life due to the debilitating and unpredictable nature of the disease which is why new options are important.”

Leave a Reply

Your email address will not be published. Required fields are marked *